Plain Language Summaries is part of Taylor & Francis Group.

  • Taylor & Francis
  • About us
  • Our journals
  • Our Digital Hubs

Taylor & Francis Group is a trading division of Informa that operates through various Informa legal entities including, but not limited to, Informa UK Limited, with the registered address at 5 Howick Place, London, SW1P 1WG, UK.

Taylor & Francis
logo
 
  • How to
  • FAQs
  • Publications
  • Advisory Panel
    • Plain Language Advisors
    • Scientific Content Advisors
  • Supporters
  • Blog
  • About us
  • Contact Us

Dementia

25th Feb 2026

Treating agitation with brexpiprazole in different Alzheimer’s dementia patient subgroups: a plain language summary

25th Feb 2026

Side-effect profile of brexpiprazole for agitation in people with Alzheimer’s dementia: a plain language summary

This is a plain language summary of an article published inthe journal Brain. People with Alzheimer’s disease may receivetreatments that target amyloid-β – a protein in the brain thatis one of the key characteristics of Alzheimer’s disease whenit is present in higher levels than normal. This article is aboutamyloid-related imaging abnormalities (ARIA), which can beadverse events for people with Alzheimer’s disease receivingantibody treatments targeting amyloid-β (known as anti–amyloid-β antibody treatments). This article also discusses waysto identify and manage ARIA.
26th Jun 2024

A plain language summary discussing amyloid-related imaging abnormalities (ARIA) and their characteristics

This is a plain language summary of an article published in the Journal of Alzheimer’s Disease. It describes an adhesive patch placed on the skin’s surface, also referred to as a transdermal delivery system (or TDS), that delivers donepezil (called donepezil TDS going forward) through the skin of patients with mild, moderate, and severe dementia of the Alzheimer’s type. This summary focuses on how fast and how much of the medication donepezil enters the body through the skin, and how it compares with taking a pill form of donepezil by mouth (oral donepezil). This summary also looks at how much donepezil is circulating through the body with the use of the once-a-week donepezil TDS versus the once-a-day donepezil pill. We show that the same amount of donepezil circulates through the body when donepezil TDS is used once a week as when a participant takes an oral donepezil pill once a day.
14th Sep 2023

A plain language summary describing once-a-week donepezil transdermal system’s bioequivalence to oral donepezil in healthy volunteers

12th Apr 2023

Plain Language Summary: Amyloid-β pathway in Alzheimer’s disease

Copyright © 2026 · Plain Language Summaries · Terms and conditions · Privacy policy · Cookie policy